Drug General Information (ID: DDI67NYIBZ)
Drug Name			Lepirudin		Drug Info		Mifepristone		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antithrombotic Agents				Uterotonic Agents
Structure

Mechanism of Lepirudin-Mifepristone Interaction (Severity Level: Major)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Lepirudin				Mifepristone
Mechanism		Risk of bleeding Anticoagulant				Risk of bleeding
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Lepirudin and Mifepristone

Recommended Action
Management		Concurrent anticoagulant therapy is considered a contraindication in the use of mifepristone for pregnancy termination. When used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome, mifepristone treatment should be administered cautiously in women who are receiving anticoagulant therapy. Patients who experience vaginal bleeding should be referred to a gynecologist for further evaluation.

References
1	Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
2	Product Information. Mifeprex (mifepristone) Danco Laboratories, New York, NY.